Studies Conducted at University of Auckland on Carcinomas Recently Reported (Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news originating from Auckland, New Zealand, by NewsRx correspondents, research stated, "SN 28049 is a new DNA-binding topoisomerase II poison identified by its curative activity against the murine colon 38 carcinoma. Previous studies showed activity to be associated with selective drug accumulation and retention in tumour tissue."
Our news journalists obtained a quote from the research from the University of Auckland, "Retention varied widely among different tumours and was related to antitumour activity. We determined whether differences in the uptake and retention of SN 28049 could be observed in vitro. The Co38P and LLTC lines were derived from the murine colon 38 carcinoma and Lewis lung carcinoma (3LL), respectively. The NZM4, NZM10 and NZM52 human melanoma lines, as well as the CCRF/CEM, CEM/VLB100 and CEM/E1000 human leukaemia lines were also utilised. Cell-associated drug was measured by liquid chromatography-mass spectrometry, laser-scanning confocal microscopy and fluorescence microscopy. Data for SN 28049 were compared for four SN 28049 analogues, for the structurally related drug N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) and for doxorubicin. Cellular uptake of SN 28049 was rapid and associated with increased fluorescence in cytoplasmic vesicles or bodies. SN 28049 uptake after an incubation time of 1 h varied widely with different cell lines (2-98 pmol/10(6) cells) and did not correlate with growth inhibitory concentrations (IC50 values), which also varied widely (1.2-19 nM). Changes in the length of the N-linked side chain of SN 28049 had large effects on drug uptake by Co38P cells. SN 28049 uptake by CCRF/CEM cells was only slightly affected by the expression of P-glycoprotein (CEM/VLB100) or MRP1 protein (CEM/E1000). As measured by cytoplasmic fluorescence, SN 28049 was taken up rapidly and retained strongly by Co38P cells, DACA was taken up rapidly and retained poorly, and doxorubicin was taken up slowly and retained moderately. The results suggest that SN 28049 is actively transported into cytoplasmic vesicles."
According to the news editors, the research concluded: "While vesicle-associated drug is not important for intrinsic cytotoxicity, it may play a key role as a 'slow release' form that modifies pharmacokinetics in multicellular structures such as tumours."
For more information on this research see: Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. Cancer Chemotherapy and Pharmacology, 2014;74(1):25-35. Cancer Chemotherapy and Pharmacology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Cancer Chemotherapy and Pharmacology - www.springerlink.com/content/0344-5704/)
The news correspondents report that additional information may be obtained from Y.Y. Chen, University of Auckland, Dept. of Pharmacol & Clin Pharmacol, Auckland 1142, New Zealand. Additional authors for this research include P.B. Lukka, W.R. Joseph, G.J. Finlay, J.W. Paxton, M.J. McKeage and B.C. Baguley (see also Oncology).
Keywords for this news article include: Auckland, Oncology, Carcinoma, Cytoplasm, Topoisomerase, Intracellular Space, Enzymes and Coenzymes, Australia and New Zealand
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC